Zevra Therapeutics Future Growth
Future criteria checks 6/6
Zevra Therapeutics is forecast to grow earnings and revenue by 63.6% and 42% per annum respectively. EPS is expected to grow by 63.3% per annum. Return on equity is forecast to be 190.8% in 3 years.
Key information
63.6%
Earnings growth rate
63.3%
EPS growth rate
| Pharmaceuticals earnings growth | 23.0% |
| Revenue growth rate | 42.0% |
| Future return on equity | 190.8% |
| Analyst coverage | Good |
| Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 159 | 28 | 12 | 14 | 5 |
| 12/31/2025 | 91 | -20 | -23 | -30 | 6 |
| 12/31/2024 | 29 | -69 | -42 | -50 | 6 |
| 12/31/2023 | 27 | -46 | -34 | -34 | N/A |
| 9/30/2023 | 17 | -40 | -22 | -22 | N/A |
| 6/30/2023 | 17 | -32 | -24 | -24 | N/A |
| 3/31/2023 | 9 | -51 | -19 | -19 | N/A |
| 12/31/2022 | 10 | -27 | -19 | -19 | N/A |
| 9/30/2022 | 11 | -35 | -15 | -15 | N/A |
| 6/30/2022 | 10 | -30 | -11 | -11 | N/A |
| 3/31/2022 | 20 | -17 | 9 | 9 | N/A |
| 12/31/2021 | 29 | -63 | 10 | 10 | N/A |
| 9/30/2021 | 28 | -65 | 10 | 10 | N/A |
| 6/30/2021 | 28 | -66 | 12 | 12 | N/A |
| 3/31/2021 | 23 | -55 | -3 | -3 | N/A |
| 12/31/2020 | 13 | -13 | -2 | -2 | N/A |
| 9/30/2020 | 12 | -14 | -4 | -4 | N/A |
| 6/30/2020 | 22 | -8 | -5 | -5 | N/A |
| 3/31/2020 | 15 | -18 | -15 | -15 | N/A |
| 12/31/2019 | 13 | -25 | -24 | -24 | N/A |
| 9/30/2019 | 11 | -24 | -36 | -36 | N/A |
| 6/30/2019 | N/A | -42 | -49 | -49 | N/A |
| 3/31/2019 | N/A | -43 | -51 | -51 | N/A |
| 12/31/2018 | N/A | -56 | -54 | -54 | N/A |
| 9/30/2018 | N/A | -62 | -46 | -46 | N/A |
| 6/30/2018 | N/A | -57 | -40 | -40 | N/A |
| 3/31/2018 | N/A | -53 | -38 | -38 | N/A |
| 12/31/2017 | N/A | -43 | -33 | -33 | N/A |
| 9/30/2017 | N/A | -43 | N/A | -36 | N/A |
| 6/30/2017 | N/A | -45 | N/A | -34 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -17 | N/A | -30 | N/A |
| 9/30/2016 | N/A | -16 | N/A | -27 | N/A |
| 6/30/2016 | N/A | -13 | N/A | -23 | N/A |
| 3/31/2016 | N/A | -52 | N/A | -20 | N/A |
| 12/31/2015 | N/A | -55 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -57 | N/A | -21 | N/A |
| 6/30/2015 | N/A | -55 | N/A | -20 | N/A |
| 3/31/2015 | N/A | -29 | N/A | -18 | N/A |
| 12/31/2014 | N/A | -24 | N/A | -15 | N/A |
| 9/30/2014 | N/A | -14 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZVRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: ZVRA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ZVRA is expected to become profitable in the next 3 years.
Revenue vs Market: ZVRA's revenue (42% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ZVRA's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZVRA's Return on Equity is forecast to be very high in 3 years time (190.8%).